Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?

IF 0.8 Q4 RESPIRATORY SYSTEM Respirology Case Reports Pub Date : 2024-08-19 eCollection Date: 2024-08-01 DOI:10.1002/rcr2.70007

Hideto Iguchi, Hiroaki Akamatsu, Yoshimitsu Hirai, Takahito Nakaya, Aya Fusamoto, Yumi Yata, Takahiro Nagai, Daiki Kitahara, Toshiaki Takakura, Yoshiharu Nishimura, Nobuyuki Yamamoto

{"title":"Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?","authors":"Hideto Iguchi, Hiroaki Akamatsu, Yoshimitsu Hirai, Takahito Nakaya, Aya Fusamoto, Yumi Yata, Takahiro Nagai, Daiki Kitahara, Toshiaki Takakura, Yoshiharu Nishimura, Nobuyuki Yamamoto","doi":"10.1002/rcr2.70007","DOIUrl":null,"url":null,"abstract":"<p><p>Neoadjuvant therapy with nivolumab improves event-free survival (EFS) in patients with resectable non-small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic responses using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) before and after neoadjuvant treatment to explore its surrogacy for pathological complete response (pCR). We describe three patients with squamous cell lung carcinoma who underwent neoadjuvant therapy with nivolumab plus chemotherapy, followed by surgery. In Cases 1 and 2, preoperative tumour response were PR per RECIST and demonstrated marked metabolic response on FDG-PET after neoadjuvant therapy, with both resected tumours showing a pCR. On the other hand, Case 3 showed a tumour response before surgery (PR per RECIST), however, the tumour, maintained FDG uptake (19.5 → 15.1), and the resected tumour remained residual cells (RVT, 15%). Thus, reduction of FDG uptake on FDG-PET can predict the pathological response to neoadjuvant therapy with nivolumab.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333152/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Neoadjuvant therapy with nivolumab improves event-free survival (EFS) in patients with resectable non-small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic responses using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) before and after neoadjuvant treatment to explore its surrogacy for pathological complete response (pCR). We describe three patients with squamous cell lung carcinoma who underwent neoadjuvant therapy with nivolumab plus chemotherapy, followed by surgery. In Cases 1 and 2, preoperative tumour response were PR per RECIST and demonstrated marked metabolic response on FDG-PET after neoadjuvant therapy, with both resected tumours showing a pCR. On the other hand, Case 3 showed a tumour response before surgery (PR per RECIST), however, the tumour, maintained FDG uptake (19.5 → 15.1), and the resected tumour remained residual cells (RVT, 15%). Thus, reduction of FDG uptake on FDG-PET can predict the pathological response to neoadjuvant therapy with nivolumab.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新辅助化疗加 nivolumab 后的 FDG-PET 能否预测非小细胞肺癌的残留疾病？

使用尼妥珠单抗进行新辅助治疗可提高可切除非小细胞肺癌患者的无事件生存期（EFS），而病理完全反应是延长无事件生存期的预测指标。我们使用18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）评估了新辅助治疗前后的代谢反应，以探索其对病理完全反应（pCR）的替代作用。我们描述了三名鳞状细胞肺癌患者的情况，他们接受了新辅助治疗，使用了 nivolumab 加化疗，随后进行了手术。在病例 1 和 2 中，术前肿瘤反应根据 RECIST 均为 PR，并且在新辅助治疗后的 FDG-PET 上显示出明显的代谢反应，切除的肿瘤均显示出 pCR。另一方面，病例 3 在术前出现肿瘤反应（RECIST PR），但肿瘤仍保持 FDG 摄取（19.5 → 15.1），切除的肿瘤仍有残留细胞（RVT，15%）。因此，FDG-PET上FDG摄取量的降低可以预测尼伐单抗新辅助治疗的病理反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.